Thromb Haemost 1972; 27(02): 228-233
DOI: 10.1055/s-0038-1649360
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Purification of Activated Hageman Factor from Human Granulocytes[*]

J Prokopowicz
1   Institute of Physiology and Biochemistry, Department of Clinical Biochemistry, Medical School, Bialystok 8, Poland
,
N Wołosowicz
1   Institute of Physiology and Biochemistry, Department of Clinical Biochemistry, Medical School, Bialystok 8, Poland
,
M Szmitkowski
1   Institute of Physiology and Biochemistry, Department of Clinical Biochemistry, Medical School, Bialystok 8, Poland
› Author Affiliations
Further Information

Publication History

Publication Date:
29 June 2018 (online)

Summary

Activated Hageman factor has been isolated from human granulocytes, utilizing aluminium hydroxide gel, diatomaceous earth, CM-cellulose. The preparation was applied on the column prepared from DEAE-Sephadex A-50. Two peaks with Hageman activity were obtained. The product was purified 4162-18750-fold as measured by the method of Schoenmakers et al.

The preparation was devoid of factor I, II, III, V, VIII, IX and plasminogen. Some relationship between granulocyte and plasma Hageman factor are briefly discussed.

* Aided in part by Polish Academy of Science, Department II.


 
  • References

  • 1 Cohn Z. A, Hirsch J. G. The isolation and properties of the specific cytoplasmic granules of rabbit polymorphonuclear leukocytes. J. exp. Med 112: 983 1960;
  • 2 Didisheim P. Purification of Hageman factor. Fed. Proc. 20. 1961
  • 3 Dixon M, Webb E. C. Enzymes. 51 Spottiswoode Ballatyne and CoLTD. London and Colchester: 1959
  • 4 Ellis S, Simjpson M. E. The chromatography of growth hormone on cellulose derivatives. J. biol. Chem 220: 939 1956;
  • 5 Haanen G. F, Hommes H, Benraad H, Morselt G. A case of Hageman factor deficiency and a method to purity the factor. Thrombos. Diathes. haemorrh. (Stuttg) 05: 201 1961;
  • 6 Kekwick R. A, Mackay M. E, Nance M. H, Record B. R. The purification of human fibrinogen. Biochem. J 60: 671 1955;
  • 7 Koller F, Loeliger A, Duckert E. Experiments on a new clotting factor (factor VII). Acta haemat. (Basel) 06: 1 1951;
  • 8 Margolis J. Plasma pain-producing substance and blood clotting. Nature 180: 1404 1957;
  • 9 Margolis J. Activation of a permeability factor in plasma by contact with glass. Nature 181: 635 1958;
  • 10 Niewiarowski S. L’adsorption des facteurs des systeme fibrinolytique par la bentonite. Pathol. Biol 07: 2557 1959;
  • 11 Niewiarowski S, Prou-Wartelle O. Rôle du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombos. Diathes. haemorrh. (Stuttg) 03: 593 1959;
  • 12 Niewiarowski S, Zywicka H, Latallo Z. Coagulation disorders in thrombocytemia. A study of seven cases. Thrombos. Diathes. haemorrh. (Stuttg) 07: 114 1962;
  • 13 Nossel H. L. The contact phase of blood coagulation. Blackwell Scientific Publications, LTD; Oxford: 1964
  • 14 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest 03: 201 1951;
  • 15 Rapaport S. J, Hjort P. F. The blood clotting properties of rabbit peritoneal leukocytes in vitro. Thrombos. Diathes. haemorrh. (Stuttg) 17: 222 1967;
  • 16 Rapaport S. J, Schijfman S, Patch M. J, Ware A. G. A simple specific one-stage assay for plasma thromboplastin antecedent activity. J. Lab. clin. Med 57: 771 1961;
  • 17 Ratnoff O. D, Davie E. W. The purification of activated Hageman factor (Activated Factor XII). Biochemistry 01: 967 1962;
  • 18 Ratnoff O. D, Davie E. W, Mallet D. L. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest 40: 813 1961;
  • 19 Schiffman S, Rapaport S. J, Ware A. G, Mehl J. W. Separation of PTA and HF from human plasma. Proc. Soc. exp. Biol. (N.Y) 105: 453 1960;
  • 20 Schoenmakers J. G. G, Kurstjens R. M, Haanen G, Zilliken F. Purification of activated bovine Hageman factor. Thrombos. Diathes. haemorrh. (Stuttg) 09: 546 1963;
  • 21 Soulier J. P, Larrieu M. J. Nouvell methode de diagnostic de l’hemophilie. Dosage des facteurs antihemophiliques A et B. Sang 24: 205 1953;
  • 22 Szpilman H, Prokopowicz J, Niewiarowski S. Distribution of procoagulant activity in the subcellular fractions of human granulocytes. Experientia (Basel) 25: 77 1969;
  • 23 Webster M. E, Ratnoff O. D. Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature 192: 180 1961;